This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	Oncofetal antigen 5T4 (TPBG; 5T4)	<p>Patient sample and mouse studies suggest killing 5T4-positive cells could help treat NSCLC. In NSCLC patients, high 5T4 expression was associated with decreased time to recurrence and overall survival compared with low expression. In mice with patient-derived NSCLC xenografts, a toxin-conjugated anti-5T4 mAb caused tumor regression without regrowth at three months, whereas vehicle or toxin-conjugated control mAb did not. Pfizer Inc. did not disclose next steps, which could include identifying additional targets for NSCLC.</p> <p>Anyara, a 5T4 antibody combined with a mutated staphylococcal enterotoxin A (SEA) from Active Biotech AB, is in Phase III testing for renal cancer and Phase I testing for NSCLC and pancreatic cancer.</p> <p>TroVax, a modified vaccinia virus Ankara (MVA) against 5T4 from Oxford BioMedica plc, is in Phase II testing for multiple cancers.</p> <p>Oxford BioMedica and Pfizer also have an anti-5T4 antibody in preclinical development for cancer.</p> <p>SciBX 4(20); doi:10.1038/scibx.2011.570 Published online May 19, 2011</p>	Patent and licensing status undisclosed	<p>Damelin, M. <i>et al. Cancer Res.</i>; published online May 3, 2011; doi:10.1158/0008-5472.CAN-10-3919</p> <p>Contact: Marc Damelin, Pfizer Inc., Pearl River, N.Y. e-mail: marc.damelin@pfizer.com</p>